Amlitelimab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Amlitelimab
- amlitelimab
- Amlitelimab
- amlitelimab [INN]
- AMLITELIMAB [USAN]
- Amlitelimab [WHO-DD]
- amlitelimab inn
- amlitelimab usan
- amlitelimab who dd
- Immunoglobulin G4 [235-proline,242-glutamic acid], anti-(human OX40 ligand) (human monoclonal KY1005-2D10 γ4-chain), disulfide with human monoclonal KY1005-2D10 κ-chain, dimer
- immunoglobulin g4 235 proline 242 glutamic acid anti human ox40 ligand human monoclonal ky1005 2d10 γ4 chain disulfide with human monoclonal ky1005 2d10 κ chain dimer
- ky 1005
- ky 1005 2d10
- Ky-1005
- KY-1005
- KY-1005-2D10
- ky1005
- Ky1005
- KY1005
- ky1005 2d10
- KY1005-2D10
- sar 445229
- SAR-445229
- sar445229
- SAR445229
- CAS registry numbers
- 2378692-15-8
- ChEMBL ID
- CHEMBL4594569
- FDA ingredient codes (UNII)
- YZ6BH6TN8P
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -mab
Mechanisms of action
- Mechanism
- Tumor necrosis factor ligand superfamily member 4 inhibitor
- Action type
- Inhibitor
- Target
- Tumor necrosis factor ligand superfamily member 4
- Protein identifier
- P23510
Open Targets mechanisms
- Mechanism
- Tumor necrosis factor ligand superfamily member 4 inhibitor
- Action type
- Inhibitor
- Target
- Tumor necrosis factor ligand superfamily member 4
- Condition
- Dermatitis, Atopic
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000274
- Subject identifier
- D003876
- Condition
- Immune System Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000540
- Subject identifier
- D007154
- Condition
- Alopecia Areata
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004192
- Subject identifier
- D000506
- Condition
- Autoimmune Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0005809
- Subject identifier
- D001327
- Condition
- Eczema
- Highest recorded phase
- 2
- Condition identifier
- HP:0000964
- Subject identifier
- D004485
- Condition
- Hidradenitis
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002260
- Subject identifier
- D016575
- Condition
- Asthma
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004979
- Subject identifier
- D001249
- Condition identifier
- EFO_0000274
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000540
- Highest recorded phase
- 1
- Condition identifier
- EFO_0004192
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005809
- Condition identifier
- MONDO_0002260
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004979
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004980
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005100
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005130
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005340
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006559
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007179
- Condition identifier
- MONDO_0015925
- Highest recorded phase
- 2
- NCT03161288
- NCT04449939
- NCT05131477
- NCT05492578
- NCT05769777
- NCT06015308
- NCT06130566
- NCT06181435
- NCT06224348
- NCT06241118
- NCT06407934
- NCT05421598
- NCT06118099
- NCT06444451
- Prodrug
- No
- Inorganic
- No
- Natural product
- No
- Component
- Heavy chain
- Type
- Protein
- Sequence
- EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYAMNWVRQAPGKGLEWVSTISGSGGATRYADSVKGRFTISRDNSRNTVYLQMNSLRVEDTAVFYCTKDRLIMATVRGPYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22'-96' $ 23''-88'' $ 23'''-88''' $ 134''-194'' $ 134'''-194''' $ 141-214'' $ 141'-214''' $ 154-210 $ 154'-210' $ 233-233' $ 236-236' $ 268-328 $ 268'-328' $ 374-432 $ 374'-432'
- Component
- Light chain
- Type
- Protein
- Sequence
- DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPNLLIYAASSLQSGVPSRFSGSGSETDFTLTISSLQPEDFATYYCQQSHSVSFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Glycosylation sites (N)
- Sequence
- 304 $ 304'
Related records
Trials (21)
- A Bioequivalence Study of Amlitelimab Delivered by 2 Different Devices in Healthy Adult Participants
- A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
- A PK Comparability Study of Two Different Amlitelimab Drug Products in Healthy Participants
- A Study of KY1005 in Healthy Volunteers
- A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis
- A Study of Subcutaneous KY1005 in Healthy Volunteers
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
- A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
- A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
- An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates
- Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma
- Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
- Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
- Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
- Platform Clinical Study for Conquering Scleroderma
- Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
In development for (6)
- Alopecia areata Phase 2
- Asthma Phase 2
- Atopic eczema Phase 3
- Autoimmune disease Phase 1
- Hidradenitis Phase 2
- Immune system disorder Phase 1
Targets (1)
- TNFSF4 Tumor necrosis factor ligand superfamily member 4 inhibitor